AbbVie Inc. (ABBV) |
|
138.49 0.85 (0.62%)
|
06-09 14:03 |
|
Open: |
137.56 |
Pre. Close: |
137.64 |
|
High:
|
139.1858 |
Low:
|
137.08 |
|
Volume:
|
1,784,923 |
Market Cap:
|
244,337(M) |
|
|
|
Technical analysis |
as of: 2023-06-09 1:43:03 PM |
|
Short-term rate:
|
 |
| Stoxline posted a BUY today, same as yesterday. Upward movement continues. |
|
Mid-term rate:
|
 |
| Target: |
Six months: 166.31 One year: 174.47 |
| Support: |
Support1: 131.1 Support2: 109.07 |
| Resistance: |
Resistance1: 142.39 Resistance2: 149.38 |
| Pivot: |
138.63  |
| Moving Average: |
MA(5): 137  MA(20): 140.17
MA(100): 150.74 MA(250): 149.64 |
| MACD: |
MACD(12,26): -3.7 Signal(9): -4.1 |
| Stochastic oscillator: |
%K(14,3): 41.6 %D(3): 35.9 |
| RSI: |
RSI(14): 40.8 |
| 52-week: |
High: 168.11 Low: 131.1 |
| Average Vol(K): |
3-Month: 5,818 (K) 10-Days: 6,485 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ ABBV ] has closed above bottom band by 49.7%. Bollinger Bands are 1% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
138.02 - 138.55 |
138.55 - 139.16 |
|
Low:
|
134.54 - 135.12 |
135.12 - 135.78 |
|
Close:
|
136.57 - 137.49 |
137.49 - 138.56 |
|
Company Description |
|
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois. |
Headline News |
Fri, 09 Jun 2023
Dorsey Wright & Associates Purchases Shares of 16912 AbbVie Inc ... - MarketBeat
Fri, 09 Jun 2023
Validea Detailed Fundamental Analysis - ABBV - Nasdaq
Fri, 09 Jun 2023
Here is What to Know Beyond Why AbbVie Inc. (ABBV) is a Trending ... - Nasdaq
Wed, 07 Jun 2023
Should You Invest in AbbVie (ABBV)? - Yahoo Finance
Tue, 06 Jun 2023
AbbVie Inc. (ABBV) to Present at the Goldman Sachs 44th Annual ... - InvestorsObserver
Mon, 05 Jun 2023
What do the Fundamentals Predict for AbbVie Inc (ABBV) Stock? - InvestorsObserver
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Outperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Outperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NYSE |
| Sector: Healthcare |
| Industry: Drug Manufacturers—General |
| Shares Out. |
1,760 (M) |
| Shares Float |
1,760 (M) |
|
% Held by Insiders
|
0.1 (%) |
|
% Held by Institutions
|
71.4 (%) |
|
Shares Short
|
11,970 (K) |
|
Shares Short P.Month
|
15,140 (K) |
Stock Financials |
|
EPS
|
4.23 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
7.53 |
|
Profit Margin (%)
|
13.3 |
|
Operating Margin (%)
|
36.9 |
|
Return on Assets (ttm)
|
9.4 |
|
Return on Equity (ttm)
|
51.2 |
|
Qtrly Rev. Growth
|
-9.7 |
|
Gross Profit (p.s.)
|
23.59 |
|
Sales Per Share
|
32.23 |
|
EBITDA (p.s.)
|
16.77 |
|
Qtrly Earnings Growth
|
-95 |
|
Operating Cash Flow
|
24,230 (M) |
|
Levered Free Cash Flow
|
21,600 (M) |
Stock Valuations |
|
PE Ratio
|
32.68 |
|
PEG Ratio
|
-3 |
|
Price to Book value
|
18.4 |
|
Price to Sales
|
4.29 |
|
Price to Cash Flow
|
10.06 |
Stock Dividends |
|
Dividend
|
1.48 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
1% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
